Showing 941-950 of 1318 results for "".
- Long-acting Reversible Contraception Linked with Acne Young Adults: Analysishttps://practicaldermatology.com/news/relationship-between-long-acting-reversible-contraception-and-acne-in-a-cohort-of-adolescents-and-young-adults/2462264/The use of progestin-only long-acting reversible contraception (LARC) may have an increased risk of developing acne or experiencing worsening of acne symptoms, a new analysis indicates. "Few studies have focused primarily on the effects of hormonal LARC on the developmen
- PSORRO: Oral Roflumilast Linked with Weight Loss in Patients with Psoriasishttps://practicaldermatology.com/news/effects-of-oral-roflumilast-therapy-on-body-weight-and-cardiometabolic-parameters-in-patients-with-psoriasis-results-from-a-randomized-controlled-trial-psorro/2462256/Roflumilast was associated with a decrease in appetite and weight loss in patients with psoriasis, according to a new study in JAAD. "Recent evidence indicates that roflumilast holds a therapeutic potential in psoriasis, a chronic inflammatory disease linked to overweight/
- Study: Transgender Individuals Experience Stigma, Treatment Barriershttps://practicaldermatology.com/news/lived-experience-of-acne-and-acne-treatment-in-transgender-patients/2462206/New research sheds light on the lived experiences of transgender individuals who have acne. "While acne is common in transgender and gender-diverse people and is associated with gender-affirming hormone therapy, little research has examined these factors and their impact in g
- Vidac Queues Up Phase 2b Study for Potential Actinic Keratosis Therapyhttps://practicaldermatology.com/news/vidac-pharma-to-conduct-phase-2b-study-for-actinic-keratosis-therapeutic-candidate-vda-1102-with-centroderm/2462192/Vidac Pharma Holdings recently announced the commencement of a Phase 2b trial for its candidate therapy (VDA-1102) to treat actinic keratosis (AK), and has engaged with a research team from a leading clinical dermatology clinical research institute (CentroDerm GmbH). According to the ma
- UW's Simpson Lab Awarded $590K to Study Hailey-Hailey Diseasehttps://practicaldermatology.com/news/uws-simpson-lab-awarded-590k-to-study-hailey-hailey-disease/2462172/The Simpson Lab at the University of Washington has been awarded a three-year $590K grant by the LEO Foundation for ongoing research in Hailey-Hailey disease (HHD). Funding from this award will support Simpson Lab personnel and provide supplies for research aimed at investigating how mu
- Strength in Numbers: IPC, IFPA, and ILDS Presidents Sign Letter of Commitmenthttps://practicaldermatology.com/news/strength-in-numbers-ipc-ifpa-and-ilds-presidents-sign-letter-of-commitment/2462144/Hervé Bachelez, MD, PhD, President of the International Psoriasis Council (IPC), Hoseah Waweru, MD, President of the International Federation of Psoriasis Associations (IFPA), and Henry W. Lim MD, President of the International League of Dermatological Societies (ILDS) recently signed a le
- CeraVe Launches in Indiahttps://practicaldermatology.com/news/cerave-launches-in-india/2462126/L'Oréal Dermatological Beauty recently unveiled CeraVe in India. To support the launch, the brand hosted 'Skin Barrier Science - A Dermatological Summit' in Mumbai, with dermatologists, experts, and partners from all over India and t
- Potential Eczema Breakthrough: IL-31 Feedback Loop Causes the Urge to Itch and Cools Nearby Inflammationhttps://practicaldermatology.com/news/potential-eczema-breakthrough-il-31-feedback-loop-causes-the-urge-to-itch-and-cools-nearby-inflammation/2462077/In a breakthrough that could transform how doctors treat conditions from eczema to allergies, scientists at UC San Francisco (UCSF) have discovered a feedback loop centered on a single immune protein called IL-31 that causes the urge to itch and dials back nearby inflammation.
- Tralokinumab Controls AD Over the Long Termhttps://practicaldermatology.com/news/adtralza-tralokinumab-controls-ad-over-the-long-term/2462069/Continuous use of Leo Pharma’s Adtralza (tralokinumab) provided long-term disease control in adult patients with moderate-to-severe atopic dermatitis (AD), according to a post hoc, interim, subgroup analysis of the ongoing ECZTEND study presented at the European Academy of Dermatology and V
- Dermavant’s VTAMA Rapidly Eases Itch in ADhttps://practicaldermatology.com/news/dermavants-vtama-rapidly-eases-itch-in-ad/2462065/Dermavant’s VTAMA (tapinarof) Cream, 1% reduces pruritus in adults and kids with atopic dermatitis as early as 24 hours after the first application, according to new data from ADORING 1 and ADORING 2 presented at the European Academy of Dermatology and Venereology (